Eli Lilly and Company LLY
will host a conference call to discuss key elements of the trial design for
EXPEDITION3, its third Phase 3 trial for solanezumab. Lilly's solanezumab is a
monoclonal antibody being studied as a potential therapy for patients with
mild Alzheimer's disease. The conference call will be held from 9:00 a.m. to
9:45 a.m. EDT on Friday, July 12, 2013.
A live audio webcast will be available on the Webcasts & Presentations section
of Lilly's Investor website at http://investor.lilly.com/events.cfm.
Subsequently, a replay of the presentation will be available on this same
website.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in